Erasca Entered into a Research Collaboration with MD Anderson for RAS/MAPK-Driven Cancers
Shots:
- The companies collaborated to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway as monothx. or combination therapies
- The collaboration will initially focus on Erasca's first MAPKlamp combination which consists of ERAS-007 (studied in multiple ongoing trials, incl. NSCLC & GI malignancies) & ERAS-601 in multiple ongoing trials in KRAS/NRAS/BRAF wildtype) CRC & HPV- advanced HNSCC
- The collaboration helps to broaden the evaluation of ERAS-007 & ERAS-601 in combination with SoC agents, incl. Erasca’s pipeline programs i.e., ERAS-4 (KRAS G12D inhibitor). Both companies will conduct preclinical & clinical studies on NSCLC & GI malignancies & other indications
Ref: GlobeNewswire | Image: Erasca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
